Company Overview - Mercurity Fintech Holding Inc. (MFH) is a blockchain-powered fintech group and a member of the Russell 2000 Index, focusing on bridging traditional finance and digital innovation [6] - The company offers a range of services including digital assets, financial advisory, and capital markets solutions through its subsidiaries [6] Leadership Appointment - Peter Nobel has been appointed as Independent Director, while Wilfred Daye, the Chief Strategy Officer, has been appointed as Director on the Board of Directors [1] - Peter Nobel is recognized for his leadership in global sustainability and ethical governance, having held senior roles in companies like Alfa Laval and SWEP International [2] Strategic Vision - The insights from Peter Nobel are expected to support MFH's long-term vision of aligning financial innovation with sustainability, transparency, and global institutional standards [3] - MFH is focused on building a next-generation financial infrastructure that integrates Web3, AI, and digital capital markets, with initiatives including Bitcoin and Solana treasury strategies and AI-driven regulatory technology [3] Governance and Ethical Legacy - The appointment of Nobel is seen as a bridge between traditional finance's institutional credibility and the innovative spirit required for digital assets [4] - Nobel's work with the Nobel Sustainability Trust aims to extend Alfred Nobel's vision of benefiting humanity into modern challenges, including climate governance and responsible capital [4] Industry Perspective - Peter Nobel emphasizes that the evolution of finance through blockchain and digital assets represents a significant shift in value movement within the global economy [5] - He highlights the importance of transparency, sustainability, and ethical governance in guiding financial innovation to serve broader human interests [5]

BOCA RATON, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- On August 20, 2025, NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT) successfully closed an offering of 2,000,000 depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of the Company's 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), with a liquidation preference of $1,000 per share (equivalent to $25.00 per Depositary Share). The offering generat ...

No change to Nasdaq listing; common shares continue to be listed under symbol "POET"TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- POET Technologies Inc. ("POET" or the "Company") (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today announced that it will shortly be proceeding with the previously-announced voluntary delisting of its com ...

Core Insights - Jiaozhou, Qingdao is a key area within the Shanghai Cooperation Organization (SCO) Demonstration Zone, featuring a strong manufacturing base with over 15,000 industrial enterprises and a total output value exceeding 160 billion yuan in 2024 [1][2]. Industrial Development Strategy - The city is implementing targeted measures to build an innovation-driven industrial system, focusing on industrial strategy research, sci-tech innovation, R&D commercialization, and industrial integration [2]. - Initiatives such as "One Town, One Industry Iterative Innovation" and "Three-Industry Integration Development" have been launched to enhance industrial capabilities [2]. Industrial Clusters - Jiaozhou has established seven provincial-level industrial clusters, including specialty food industries and home appliances [3]. - The city also hosts two national-level clusters: Smart Home Appliances and Power Steel Structures, showcasing its advanced manufacturing capabilities [4]. Advanced Manufacturing - Jiaozhou is home to leading manufacturing companies like Qingdao CIMC Reefer Container Manufacture Co., Ltd., Alfa Laval (Qingdao) Industrial Co., Ltd., and Haier Group, contributing to world-class production bases [4]. - The region has developed significant manufacturing facilities, including a global-leading refrigeration container R&D base and Asia's top marine boiler production base [4]. New Energy Industry - In 2025, Jiaozhou is focusing on driving the new energy industry through enhanced R&D, supportive policies, talent development, and global cooperation [5].

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic the ...

Company Overview - UAB "Orkela" is a private limited liability company established on 24 September 2015, with its legal address in Vilnius and no branches or representative offices [1] - The main activities of the company include real estate development and construction, specifically a lyceum and hotel complex in Vilnius [2] Financial Highlights - In the first half of 2025, the company incurred costs of EUR 617.3 thousand for project development and EUR 1.9 million in financing costs, while generating revenue of EUR 163.0 thousand [3] - As of 30 June 2025, the company's total assets were valued at EUR 70,169 thousand, an increase from EUR 50,695 thousand as of 31 December 2024 [3] - The Loan to Cost (LTC) ratio as of 30 June 2025 was reported at 49.46% [4] Project Development Updates - The historical part of the complex was registered as 100% completed in April 2025 [5] - The Public Institution Modern School Center commenced operations in the complex in April 2025 [5] - In June 2025, Reitan Convenience Lietuva and TNS Kantar began their operations in the premises [5]

Core Insights - LIXTE Biotechnology Holdings, Inc. is focusing on developing novel cancer therapies targeting key cellular pathways, with a particular emphasis on high-need cancer indications that currently have limited treatment options [1][10] - The company's lead compound, LB-100, is being evaluated in clinical studies aimed at enhancing the effectiveness of chemotherapy and immunotherapy in treatment-resistant cancers [1][7] Colorectal Cancer - Colorectal cancer is one of the most prevalent cancers globally, with the drug market projected to exceed $18 billion by 2028; approximately 85% of cases are microsatellite-stable (MSS) and do not respond to existing immunotherapies [2][3] - LB-100 is being studied in combination with Roche's atezolizumab in a clinical trial at the Netherlands Cancer Institute, targeting MSS colorectal cancer patients [3] Ovarian Clear-Cell Carcinoma - Ovarian clear-cell carcinoma (OCCC) accounts for about 5-10% of ovarian cancer cases, with current treatments showing limited efficacy and poor long-term outcomes; the global market for ovarian cancer therapies was valued at over $2 billion in 2023 [3][4] - LB-100 is being evaluated in combination with GlaxoSmithKline's dostarlimab in a study at MD Anderson Cancer Center and Northwestern University, with interim data expected in Q4 2025 [4] Soft-Tissue Sarcoma - Soft-tissue sarcomas are rare cancers with limited treatment advancements; the global market for therapies is projected to reach $1.5 to $2 billion by 2030 [5] - A Phase 1b clinical study is being conducted in collaboration with the Spanish Sarcoma Group to evaluate LB-100 in combination with doxorubicin, aiming to enhance chemotherapy effectiveness [6] Development Strategy - LIXTE's clinical programs are aligned with significant commercial opportunities and unmet therapeutic needs, particularly in tumors with poor responses to current immunotherapies [7][8] - LB-100 is a first-in-class PP2A inhibitor designed to sensitize tumors to other treatments, including immune checkpoint blockade and standard chemotherapy [7][10]

Core Insights - CarMax is launching a new brand positioning with the tagline "Wanna Drive?" to emphasize its customer-centric, omni-channel car-buying experience [1][4][10] - The new approach aims to empower customers by allowing them to shop online, in-store, or switch between both seamlessly, setting a new standard in the used car retail industry [3][10] Brand Positioning - The new tagline "Wanna Drive?" replaces the previous tagline that had been in use for over 20 years, reflecting the evolution of CarMax and its commitment to customer empowerment [7][10] - CarMax's omni-channel experience allows customers to have control over their car-buying journey, providing clarity and confidence [10][12] Customer Experience - CarMax has achieved its highest Net Promoter Score since the rollout of its digital capabilities, indicating increased customer satisfaction, particularly among those using online and mixed shopping options [4][10] - The company emphasizes honesty, integrity, and innovation as core values that differentiate it from traditional and online-only dealers [4][10] Marketing Campaign - The campaign features the CarMax House Band, which represents the journey of car buying and selling, with creative spots designed to resonate with customers [11][12] - The marketing strategy includes a phased rollout across various platforms, including linear TV, streaming, social media, and audio [12]

Core Viewpoint - Vornado Realty Trust has announced an agreement to purchase the 623 Fifth Avenue office condominium for $218 million, aiming to reposition and redevelop it into a premier Class A boutique office building [2][3]. Acquisition Details - The acquisition involves a 36-story building with 382,500 rentable square feet, located above the flagship Saks Fifth Avenue department store [2]. - The building is currently 75% vacant, and Vornado plans to fully redevelop it [3]. Redevelopment Plans - Vornado intends to transform the 623 Fifth Avenue building to complement its existing holdings in the Plaza District and Park Avenue, which include several prominent addresses [3]. - The expected timeline for closing the acquisition is September 2025, with redevelopment completion targeted for 2027 [4].

Core Viewpoint - Catalyst Pharmaceuticals and SERB have reached a settlement with Lupin regarding the patent litigation over FIRDAPSE, allowing Lupin to market a generic version starting February 25, 2035, pending FDA approval [1][2]. Group 1: Settlement Agreement Details - The settlement agreement resolves ongoing patent litigation between Catalyst/SERB and Lupin concerning FIRDAPSE [2]. - Lupin is prohibited from marketing its generic version of FIRDAPSE in the U.S. before February 25, 2035, unless specific circumstances arise [2]. - The agreement includes the termination of all ongoing patent litigation related to FIRDAPSE patents in the U.S. District Court for the District of New Jersey [2]. Group 2: Company Background - Catalyst Pharmaceuticals is focused on developing and commercializing treatments for rare diseases and has a strong commitment to patient care [4]. - The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [4].